Qual é o preço para Kyverna Therapeutics, Inc. (KYTX)

O preço para Kyverna Therapeutics, Inc. (KYTX) é $8.46

Qual é a capitalização de mercado para Kyverna Therapeutics, Inc. (KYTX)

A capitalização de mercado para Kyverna Therapeutics, Inc. (KYTX) é $514.33M

Histórico de Preços de Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Ano	Desempenho
2026 (TTM)	-5.16%
2025	89.56%
2024	0.00%

Ano

Desempenho

2026 (TTM)

-5.16%

2025

89.56%

2024

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.01	-13.08%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$752.76	6.28%	CH

Empresa

Preço da ação

Variação 1a%

País